OBJECTIVE: The objective of the study was to evaluate the regression, relapse, and live birth rates of early-stage endometrial cancer (EC) and atypical complex hyperplasia (ACH) with fertility-sparing treatment. STUDY DESIGN: This was a metaanalysis of the proportions from observational studies with a random-effects model and a meta-regression to explore for heterogeneity. RESULTS: Thirty-four observational studies, evaluating the regression, relapse, and live birth rates of early-stage EC (408 women) and ACH (151 women) with fertility-sparing treatment. Fertility-sparing treatment for EC achieved a pooled regression rate of 76.2%, a relapse rate of 40.6%, and a live birth rate of 28%. For ACH the pooled regression rate was 85.6%, a relapse rate of 26%, and a live birth rate of 26.3%. Twenty women were diagnosed with ovarian cancer (concurrent or metastatic) during follow-up (3.6%) and 10 progressed to higher than stage I EC (1.9%) from which 2 women died. CONCLUSION: Fertility-sparing treatment of EC and ACH is feasible and selected women can satisfy their reproductive wishes.
OBJECTIVE: The objective of the study was to evaluate the regression, relapse, and live birth rates of early-stage endometrial cancer (EC) and atypical complex hyperplasia (ACH) with fertility-sparing treatment. STUDY DESIGN: This was a metaanalysis of the proportions from observational studies with a random-effects model and a meta-regression to explore for heterogeneity. RESULTS: Thirty-four observational studies, evaluating the regression, relapse, and live birth rates of early-stage EC (408 women) and ACH (151 women) with fertility-sparing treatment. Fertility-sparing treatment for EC achieved a pooled regression rate of 76.2%, a relapse rate of 40.6%, and a live birth rate of 28%. For ACH the pooled regression rate was 85.6%, a relapse rate of 26%, and a live birth rate of 26.3%. Twenty women were diagnosed with ovarian cancer (concurrent or metastatic) during follow-up (3.6%) and 10 progressed to higher than stage I EC (1.9%) from which 2 women died. CONCLUSION: Fertility-sparing treatment of EC and ACH is feasible and selected women can satisfy their reproductive wishes.
Authors: Sinead H McEvoy; Stephanie Nougaret; Nadeem R Abu-Rustum; Hebert Alberto Vargas; Elizabeth A Sadowski; Christine O Menias; Fuki Shitano; Shinya Fujii; Ramon E Sosa; Joanna G Escalon; Evis Sala; Yulia Lakhman Journal: Abdom Radiol (NY) Date: 2017-10
Authors: Maria P Ruiz; Yongmei Huang; June Y Hou; Ana I Tergas; William M Burke; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright Journal: Am J Obstet Gynecol Date: 2017-08-24 Impact factor: 8.661
Authors: Ross F Harrison; Weiguo He; Shuangshuang Fu; Hui Zhao; Charlotte C Sun; Rudy S Suidan; Terri L Woodard; J Alejandro Rauh-Hain; Shannon N Westin; Sharon H Giordano; Larissa A Meyer Journal: Am J Obstet Gynecol Date: 2019-05-22 Impact factor: 8.661
Authors: Marcia A Ciccone; Stephanie A Whitman; Charlotte L Conturie; Niquelle Brown; Christina E Dancz; Begum Özel; Koji Matsuo Journal: Arch Gynecol Obstet Date: 2019-01-31 Impact factor: 2.344